INGELHEIM, Germany--(BUSINESS WIRE)--The RE-DUAL PCI™ trial explored anticoagulation with Pradaxa ® (dabigatran etexilate) dual therapy without aspirin in non-valvular atrial fibrillation (AF) ...

The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial compared the efficacy and safety of dabigatran (Pradax in Canada and Pradaxa in Europe), a new oral direct thrombin ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The parallel, open-label GIRAF trial randomly assigned ...

RIDGEFIELD, Conn., March 19, 2017 /PRNewswire/ -- Important new data from the RE-CIRCUIT® study show a better safety profile for Pradaxa® (dabigatran etexilate mesylate) compared to warfarin in atrial ...

Dr. Noel G. Boyle, Professor of Medicine, Ronald Reagan UCLA Medical Center, Los Angeles, talks about new medications that can work as alternatives to warfarin for atrial fibrillation patients who are ...

Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Cognitive outcomes were mostly the same between dabigatran ...

When it comes to preserving cognitive function in older patients with atrial fibrillation (AF) or flutter, the choice of oral anticoagulant doesn’t appear to matter much, according to the randomized ...

Barcelona, Spain, 30 August: The anticoagulant dabigatran is more effective than warfarin in the prevention of stroke in patients with atrial fibrillation, according to results from the RE-LY study ...

The risk of MI is lower in patients with A-fib starting treatment with a direct non-vitamin K antagonist oral anticoagulant (NOAC) rather than a vitamin K antagonist (VKA) for stroke prevention, ...

RIDGEFIELD, Conn., April 8, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa ® (dabigatran ...

Pradaxa ® showed a similar incidence of minor bleeding complications compared to warfarin (59/317 versus 54/318). There were no thromboembolic events in patients taking Pradaxa ® and one in patients ...